ACRG-U:CNSX-Acreage Holdings, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | CNSX

Last Closing Price

USD 2.77

Change

0.00 (0.00)%

Market Cap

USD 0.27B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ACRG-U Stock Forecast & Price:
Based on the Acreage Holdings, Inc stock forecasts from 1 analysts, the average analyst target price for Acreage Holdings, Inc is USD 0.00 over the next 12 months. Acreage Holdings, Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Acreage Holdings, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Acreage Holdings, Inc’s stock price was USD 2.77. Acreage Holdings, Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Acreage Holdings, Inc
No recent average analyst rating found for Acreage Holdings, Inc

About Acreage Holdings, Inc (ACRG-U:CA:CNSX)

Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York. Address: 366 Madison Avenue, New York, NY, United States, 10017

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

ETFs Containing ACRG-U:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -20.84% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.84% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.79% N/A N/A N/A N/A
Risk Adjusted Return -58.22% N/A N/A N/A N/A
Market Capitalization 0.27B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.99 N/A N/A N/A N/A
Price / Cash Flow Ratio -3.85 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -86.41% N/A N/A N/A N/A
Return on Invested Capital -43.10% N/A N/A N/A N/A
Return on Assets -19.19% N/A N/A N/A N/A
Debt to Equity Ratio 6.94% N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.19 N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.